A quantity of the quadrivalent influenza split virion vaccine produced by Changchun Institute of Biological Products Co Ltd was shipped to the Macao Special Administrative Region on Dec 10.

This was the first shipment of the vaccine to be made following its approval by the Pharmaceutical Administration Bureau of Macao in February this year, and also the first influenza vaccine from China National Biotec Group Company Limited (CNBG) to be used in the SAR.

The quadrivalent influenza split virion vaccine produced by Changchun Biological [Photo/sinopharm.com]

Changchun Biological, a subsidiary of Sinopharm's CNBG, is China's earliest research and production base for influenza vaccines, boasting extensive expertise and advanced technologies. The influenza vaccine (split virion, inactivated) produced by the company has now been on the market for 22 years, with over 90 million doses sold to date, achieving a 100 percent pass rate in lot release. In 2023, the vaccine earned prequalification from the World Health Organization, underscoring its international quality standards.

Committed to Sinopharm's global development strategy, Changchun Biological has successfully registered its quadrivalent influenza vaccine in several countries. The company is also proactively advancing international registrations for its rabies and hepatitis A vaccines.